alexa and#946;-Blockers or and#946;–Agonists? That’s the Question in the COPD Management

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences
β-Blockers or β–Agonists? That’s the Question in the COPD Management

Beta-blockers have long been known as agents posing bronchospasm in medical literature, and this has made physicians to have a reasonable fear in employing these agents for managing cardiovascular complications in the Chronic Obstructive Pulmonary Disease (COPD). On the other hand, cardiovascular co morbidities, alongside cancers, are the leading causes of mortality in mild to moderate COPD patients, and β-blockers have secured their position as one of the best distinguished cardioprotective agents with the highest effectiveness and lowest rate of side-effects.

β-Blockers or β–Agonists? That’s the Question in the COPD Management

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top